<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Interferon beta-1b: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Interferon beta-1b: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Interferon beta-1b: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10767" href="/d/html/10767.html" rel="external">see "Interferon beta-1b: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F183545"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Betaseron;</li>
<li>Extavia</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867215"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Betaseron;</li>
<li>Extavia [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F183563"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Interferon</li></ul></div>
<div class="block doa drugH1Div" id="F183548"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b>
<b>Safety: </b>In high-risk populations or in countries with high tuberculosis burden, screen for latent infections (eg, hepatitis, tuberculosis) prior to initiating therapy. For patients who screen positive for latent infections, consult infectious disease or other appropriate specialists (eg, liver specialists) regarding treatment options before initiating therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31462584']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31462584'])">Ref</a></span>). <b>Premedication: </b>Analgesics and/or antipyretics may help decrease flu-like symptoms on treatment days.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="800e2fc1-5444-4538-baf2-520898316bf7">Multiple sclerosis, relapsing</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple sclerosis, relapsing:</b> SubQ: Initial: 0.0625 mg (2 million units [0.25 mL]) every other day; gradually increase dose by 0.0625 mg every 2 weeks to a target dose of 0.25 mg (8 million units [1 mL]) every other day.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991852"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50989147"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dot drugH1Div" id="F58556265"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:0em;display:inline">Pulmonary arterial hypertension: Discontinue treatment with confirmed diagnosis.</p></div>
<div class="block doe drugH1Div" id="F183549"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F183518"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (21%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary urgency (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decrease in absolute neutrophil count (13%), leukopenia (18%; decreased white blood cell count &lt;3,000/mm<sup>3</sup>: 13%), lymphocytopenia (86%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (&gt;5 × baseline: 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (neutralizing: 17% to 45%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Inflammation at injection site (42%), injection-site reaction (78%), pain at injection site (16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (53%), ataxia (17%), chills (21%), headache (50%), hypertonia (40%), insomnia (21%), pain (42%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myalgia (23%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Flu-like symptoms (57%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (31%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (9%), hypertension (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Dermatologic disorder (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Impotence (8%), uterine hemorrhage (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Lymphadenopathy (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum aspartate aminotransferase (&gt;5 × baseline: 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Hypersensitivity reaction at injection site (4%), residual mass at injection site (2%), swelling at injection site (2%), tissue necrosis at injection site (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Malaise (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (6%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Nervous system: Suicidal ideation</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Palpitations, peripheral vascular disease, tachycardia, vasodilation</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Heavy menstrual bleeding, weight gain</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation, diarrhea, dyspepsia, nausea</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysmenorrhea, prostatic disease, urinary frequency</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety, dizziness, myasthenia, nervousness</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, lower limb cramp</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Capillary leak syndrome, cardiomyopathy, heart failure</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus, skin discoloration, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased serum triglycerides, thyroid dysfunction (including hyperthyroidism and hypothyroidism), weight loss</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia, pancreatitis, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia, hemolytic anemia, hemolytic-uremic syndrome, thrombocytopenia, thrombotic microangiopathy, thrombotic thrombocytopenic purpura</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Autoimmune hepatitis, hepatic failure, hepatic injury, hepatitis, hepatotoxicity (idiosyncratic) (Chalasani 2021), increased gamma-glutamyl transferase</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, tongue edema</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Abscess at injection site, cellulitis at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Confusion, depression, emotional lability, psychotic symptoms, seizure</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Lupus erythematosus</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm, pulmonary hypertension (including pulmonary arterial hypertension) (McGovern 2015; Health Canada Nov 2, 2016)</p></div>
<div class="block coi drugH1Div" id="F183531"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">History of hypersensitivity to natural or recombinant interferon beta, albumin (human), or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindication (not in US labeling): Decompensated liver disease (Betaseron, Extavia); current severe depression and/or suicidal ideation (Extavia)</p></div>
<div class="block war drugH1Div" id="F183515"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylaxis/hypersensitivity reactions: Allergic reactions (eg, bronchospasm, dyspnea, skin rash, tongue edema, urticaria), including anaphylaxis (rare), have been reported with use; discontinue use if anaphylaxis occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Drug-induced lupus erythematosus: Cases of drug-induced lupus erythematosus have been reported with some interferon beta products; signs and symptoms include nephritis, polyarthritis, rash, Raynaud phenomenon, and serositis. Positive serologic testing, including positive anti-nuclear and/or anti-double-stranded DNA antibody testing, may occur; discontinue treatment if signs and symptoms of drug-induced lupus erythematosus develop.</p>
<p style="text-indent:-2em;margin-left:4em;">• Flu-like symptoms: Associated with a high incidence of flu-like adverse effects; use of analgesics and/or antipyretics on treatment days may be helpful. Improvement in symptoms occurs over time.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Has been reported with beta interferons, including rare reports of hepatitis (autoimmune) and hepatic failure requiring transplant; use with caution in patients with concurrent exposure to other hepatotoxic drugs. Monitor liver function tests as clinically necessary. Consider discontinuation if serum transaminase levels increase significantly or are associated with clinical symptoms (eg, jaundice).</p>
<p style="text-indent:-2em;margin-left:4em;">• Infections: In high-risk populations or in countries with high tuberculosis burden, screen for latent infections (eg, hepatitis, tuberculosis) prior to initiating therapy. For patients who screen positive for latent infections, consult infectious disease or other specialists (eg, liver specialists) regarding treatment options before initiating therapy (AAN [Farez 2019]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Injection site reactions: Severe injection site reactions may occur, including abscess, cellulitis, edema, hypersensitivity, inflammation, mass, necrosis, and pain. Necrosis may or may not heal with continued therapy; reactions generally arise within the first 4 months of therapy but have occurred ≥1 year after initiation. Incidence of reactions tend to improve over time but may require antibiotics or surgical intervention. Patient and/or caregiver competency in injection technique should be confirmed and periodically re-evaluated. Do not inject into affected area until completely healed; if multiple lesions occur, discontinue use until they are fully healed.</p>
<p style="text-indent:-2em;margin-left:4em;">• Leukopenia: Leukopenia has been observed; routine monitoring of complete blood counts with differentials is recommended. Dose reduction may be required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neuropsychiatric disorders: Interferons have been associated with severe psychiatric adverse events (psychosis, mania, depression, suicidal behavior/ideation) in patients with and without previous psychiatric symptoms. Avoid use in severe psychiatric disorders and use caution in patients with a history of depression; patients exhibiting symptoms of depression should be closely monitored and discontinuation of therapy should be considered.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary effects: Pulmonary arterial hypertension (sometimes requiring hospitalization and one patient requiring a lung transplant) has occurred in patients without other risk factors taking interferon beta products; onset varies and may occur several years after initiation of treatment. Patients with unexplained symptoms (eg, dyspnea, new or worsening fatigue) should be evaluated for pulmonary arterial hypertension.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thrombotic microangiopathy: Cases of thrombotic microangiopathy manifesting as thrombotic thrombocytopenic purpura (TTP) or hemolytic uremic syndrome (HUS) (some fatal) have been reported with interferon beta products. Some cases may occur after several years of therapy. Monitor for new onset hypertension, thrombocytopenia, or impaired renal function; discontinue therapy and administer prompt treatment if TTP/HUS are confirmed or suspected to be due to interferon beta-1b therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Use with caution in patients with bone marrow suppression; may require increased monitoring.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with preexisting cardiovascular disease. Rare cases of new-onset cardiomyopathy and/or HF have been reported. If HF worsens in the absence of another etiology, consider discontinuation of therapy. In a scientific statement from the American Heart Association, interferon has been determined to be an agent that may either cause reversible direct myocardial toxicity or exacerbate underlying myocardial dysfunction (magnitude: moderate/major) (AHA [Page 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment or in combination with alcohol.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorder: Use with caution in patients with a history of seizure disorder.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid dysfunction: Thyroid abnormalities may develop with use; may worsen pre-existing thyroid conditions. Monitor thyroid function tests every 6 months or as clinically necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Albumin: Contains albumin, which may carry a remote risk of transmitting Creutzfeldt-Jakob or other viral diseases.</p>
<p style="text-indent:-2em;margin-left:4em;">• Latex: Some dosage forms may contain natural rubber latex.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions: </b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Immunizations: Avoid live-attenuated vaccines in patients who currently receive or have recently discontinued interferon beta-1b; consider using live-attenuated vaccines only if risk of infection is high and killed vaccines are unavailable (AAN [Farez 2019]).</p></div>
<div class="block dosfc drugH1Div" id="F46582539"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">The Extavia diluent syringe cap may contain latex.</p></div>
<div class="block foc drugH1Div" id="F183526"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Betaseron: 0.3 mg [contains albumin human]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Extavia: 0.3 mg [contains albumin human]</p></div>
<div class="block geq drugH1Div" id="F183511"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F183534"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Betaseron Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.3 mg (per each): $835.96</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Extavia Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.3 mg (per each): $635.42</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867216"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Betaseron: 0.3 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Extavia: 0.3 mg ([DSC]) [contains albumin human]</p></div>
<div class="block adm drugH1Div" id="F183528"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">For SubQ administration. The first injection should be administered under the supervision of a health care professional. Withdraw dose of reconstituted solution from the vial into a sterile syringe fitted with needle provided in manufacturer packaging (refer to manufacturer labeling for appropriate size) and inject the solution subcutaneously. Autoinjectors may be used with their corresponding prepared syringes after health care provider selects proper depth setting and injection technique (see autoinjector instructions for more details). Sites for self-injection include outer surface of the arms, abdomen (<b>except</b> 2-inch area around the navel), buttocks, and thighs. If patient is very thin, only use the thigh or outer surface of arms. Rotate SubQ injection site. Do not inject into area where skin is bruised, infected, or broken. Patient should be well hydrated. If a dose is missed, administer as soon as remembered; do not administer on 2 consecutive days. Time subsequent doses every 48 hours.</p></div>
<div class="block meg drugH1Div" id="F7874832"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Betaseron: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F103471s5202lbl.pdf%23page%3D19&amp;token=xQJV5Tov%2BsoBfbZnrE0L3whvnTRDezhKe1gQrhFMc6tQkX%2B3BBje56KoZEAqD2gvuC2By%2F7LW81d4IWxI0fVAkQuSBqBfBI36CtiVShsYDkP5FAem%2FVL0cHUrdr5Kr9w&amp;TOPIC_ID=8566" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/103471s5202lbl.pdf#page=19</a></p>
<p style="text-indent:-2em;margin-left:4em;">Extavia: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F125290s074lbl.pdf%23page%3D16&amp;token=aQICC7DMsnEt%2FSFkyejmqekwsHzcLsaN9TmcjFOgTC5Cc7sEw4pv4Q8fJYbYWwyhCX3nf%2FpvGPfF8hpj4D5kVWlCf6aqsSuj2hN6X66oyYsjrKYBHMBzLvIrqvFqS6Gx&amp;TOPIC_ID=8566" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125290s074lbl.pdf#page=16</a></p></div>
<div class="block use drugH1Div" id="F183527"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple sclerosis, relapsing:</b> Treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.</p></div>
<div class="block cyt drugH1Div" id="F13299524"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F183520"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the adverse/toxic effect of Interferons (Beta). Specifically, the risk for lymphopenia may be increased.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zidovudine: Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine. <i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F53487480"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">In general, disease-modifying therapies for multiple sclerosis (MS) are stopped prior to a planned pregnancy, except in females at high risk of MS activity (AAN [Rae-Grant 2018]). When disease-modifying therapy is needed in females planning a pregnancy (eg, high risk of disease reactivation), interferon beta-1b may be considered until pregnancy is confirmed, and in select cases (eg, women with active disease), use may be continued during pregnancy. Delaying pregnancy is recommended for females with persistent high disease activity (ECTRIMS/EAN [Montalban 2018]).</p></div>
<div class="block pri drugH1Div" id="F183535"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Data from available pregnancy registries have not observed an increased risk or pattern of major birth defects, preterm birth, or decreased birth weight following maternal use of interferon beta-1b (Coyle 2014; Romero 2015; Thiel 2016). In most cases, therapy was stopped during the first trimester after pregnancy was detected (Thiel 2016).</p>
<p style="text-indent:0em;margin-top:2em;">In general, disease-modifying therapies for multiple sclerosis (MS) are not initiated during pregnancy, except in females at high risk of MS activity (AAN [Rae-Grant 2018]). When disease-modifying therapy is needed in females planning a pregnancy (eg, high risk of disease reactivation), interferon beta-1b may be considered until pregnancy is confirmed, and in select cases (eg, women with active disease), use may be continued during pregnancy (ECTRIMS/EAN [Montalban 2018]).</p></div>
<div class="block brc drugH1Div" id="F183536"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if interferon beta-1b is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Studies conducted with interferon beta-1a show only small amounts are present in breast milk. In addition, interferon beta does not have a systemic biologic effect if given orally (Almas 2016; Fragoso 2018). According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. However, based on its chemical properties, others consider interferon beta compatible with breastfeeding (Almas 2016; Dobson 2019; Fragoso 2018).</p></div>
<div class="block mop drugH1Div" id="F183524"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Latent infection screening (eg, hepatitis, tuberculosis) in high-risk populations or in countries with high tuberculosis burden (baseline); complete metabolic panel, CBC with differential, liver function tests (1, 3, and 6 months following initiation of therapy; periodically thereafter); thyroid function tests (every 6 months in patients with history of thyroid dysfunction or as clinically necessary); assess patients who develop unexplained symptoms (eg, dyspnea, new or worsening fatigue) for pulmonary arterial hypertension; symptoms of flu, allergic or anaphylactic reactions, injection-site reactions, worsening of cardiac symptoms (in heart failure patients); sign/symptoms of depression.</p></div>
<div class="block pha drugH1Div" id="F183514"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Interferon beta-1b differs from naturally occurring human protein by a single amino acid substitution and the lack of carbohydrate side chains; mechanism in the treatment of MS is unknown; however, immunomodulatory effects attributed to interferon beta-1b include enhancement of suppressor T cell activity, reduction of proinflammatory cytokines, down-regulation of antigen presentation, and reduced trafficking of lymphocytes into the central nervous system. Improves MRI lesions, decreases relapse rate, and disease severity in patients with secondary progressive MS.</p></div>
<div class="block phk drugH1Div" id="F183530"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Limited data due to small doses used </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: 8 minutes to 4.3 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: 1-8 hours</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F183537"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Betaferon</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Betaferon | Betaferon recombinte</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Betaferon | Extavia</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Betaferon | Extavia | Interferon Beta 1b</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Betaferon | Extavia</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Betaferon | Extavia</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Betaferon | Extavia | Serobif</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Betaferon | Betaferon lyophilisat</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Betaferon</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Betaferon</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Betaferon</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Betaferon | Extavia</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Betaferon | Extavia</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Betaferon | Uribeta</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Betaferon</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Betaferon | Extavia</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Betaferon</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Betaferon | Extavia</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Betaferon | Extavia</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Betaferon | Extavia</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Betaferon | Extavia</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Betaferon | Extavia</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Betaferon</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Betaferon | Extavia</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Betaferon | Extavia</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Betaferon | Extavia</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Betaferon</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Betaferon | Extavia</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Betaferon</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Betaferon | Betaseron | Extavia</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Betaferon</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Betaferon</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Betaferon</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Betaferon | Extavia</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Betaferon | Extavia</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Betaferon | Extavia</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Betaferon</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Betaferon | Extavia | Uribeta</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Betaferon</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Betaferon</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Betaferon | Extavia</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Betaferon</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Betaferon | Uribeta</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Betaferon</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Betaferon | Extavia</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Betaseron</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Betaferon | Extavia</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Betaferon</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Betaferon | Extavia</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Betaferon | Extavia | Infibeta | Ronbetal</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Betaferon | Extavia</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Betaferon | Extavia</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Betaferon | Extavia</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Betaferon</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Betaferon</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Betaferon</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Betaferon</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">B-imunoferon-1b | Betaferon | Betpherum-1b</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-26966579">
<a name="26966579"></a>Almas S, Vance J, Baker T, Hale T. Management of multiple sclerosis in the breastfeeding mother. <i>Mult Scler Int</i>. 2016;2016:6527458. doi:10.1155/2016/6527458<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-beta-1b-drug-information/abstract-text/26966579/pubmed" id="26966579" target="_blank">26966579</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Betaseron (interferon beta-1b) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; July 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Betaseron.1">
<a name="Betaseron.1"></a>Betaseron (interferon beta-1b) [product monograph]. Mississauga, Ontario, Canada: Bayer Inc; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24935270">
<a name="24935270"></a>Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-beta-1b-drug-information/abstract-text/24935270/pubmed" id="24935270" target="_blank">24935270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33929376">
<a name="33929376"></a>Chalasani NP, Maddur H, Russo MW, Wong RJ, Reddy KR; Practice Parameters Committee of the American College of Gastroenterology. ACG Clinical Guideline: diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2021;116(5):878-898. doi:10.14309/ajg.0000000000001259<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-beta-1b-drug-information/abstract-text/33929376/pubmed" id="33929376" target="_blank">33929376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24821713">
<a name="24821713"></a>Coyle PK, Sinclair SM, Scheuerle AE, Thorp JM Jr, Albano JD, Rametta MJ. Final results from the Betaseron (interferon β-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events. <i>BMJ Open</i>. 2014;4(5):e004536. doi: 10.1136/bmjopen-2013-004536.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-beta-1b-drug-information/abstract-text/24821713/pubmed" id="24821713" target="_blank">24821713</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30612100">
<a name="30612100"></a>Dobson R, Dassan P, Roberts M, Giovannoni G, Nelson-Piercy C, Brex PA. UK consensus on pregnancy in multiple sclerosis: 'Association of British Neurologists' guidelines. <i>Pract Neurol</i>. 2019;19(2):106-114. doi: 10.1136/practneurol-2018-002060.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-beta-1b-drug-information/abstract-text/30612100/pubmed" id="30612100" target="_blank">30612100</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Extavia (interferon beta-1b) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; July 2023.</div>
</li>
<li>
<div class="reference">
                  Extavia (interferon beta-1b) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; August 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31462584">
<a name="31462584"></a>Farez MF, Correale J, Armstrong MJ, et al. Practice guideline update summary: vaccine-preventable infections and immunization in multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. <i>Neurology</i>. 2019;93(13):584-594. doi:10.1212/WNL.0000000000008157<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-beta-1b-drug-information/abstract-text/31462584/pubmed" id="31462584" target="_blank">31462584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30167914">
<a name="30167914"></a>Fragoso YD, Adoni T, Brooks JBB, et al. Practical evidence-based recommendations for patients with multiple sclerosis who want to have children. <i>Neurol Ther</i>. 2018;7(2):207-232. doi: 10.1007/s40120-018-0110-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-beta-1b-drug-information/abstract-text/30167914/pubmed" id="30167914" target="_blank">30167914</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Healthy Canadians Recalls &amp; Alerts. Interferon beta products — assessing the potential risk of pulmonary arterial hypertension. <a href="http://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/interferon-beta2-eng.php" target="_blank">http://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/interferon-beta2-eng.php</a>. Published November 2, 2016. Accessed November 16, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29708217">
<a name="29708217"></a>Kaisey M, Sicotte N, Giesser B. Multiple sclerosis management and reproductive changes: A guide for general neurologists. <i>Neurol Clin Pract</i>. 2018;8(2):142-147. doi: 10.1212/CPJ.0000000000000436.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-beta-1b-drug-information/abstract-text/29708217/pubmed" id="29708217" target="_blank">29708217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26008947">
<a name="26008947"></a>McGovern M, Judge EP, Kavanagh E, Gaine S, Lynch T. Interferon beta related pulmonary arterial hypertension; an emerging worrying entity? <i>Mult Scler Relat Disord</i>. 2015;4(3):284-286.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-beta-1b-drug-information/abstract-text/26008947/pubmed" id="26008947" target="_blank">26008947</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29352526">
<a name="29352526"></a>Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis [published correction appear in <i>Eur J Neurol</i>. 2018;25(3):605]. <i>Eur J Neurol</i>. 2018;25(2):215-237. doi: 10.1111/ene.13536.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-beta-1b-drug-information/abstract-text/29352526/pubmed" id="29352526" target="_blank">29352526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIH.1">
<a name="NIH.1"></a>National Institutes of Health. COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. <a href="https://covid19treatmentguidelines.nih.gov/" target="_blank">https://covid19treatmentguidelines.nih.gov/</a>. Updated October 9, 2020. Accessed October 16, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27400984">
<a name="27400984"></a>Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-beta-1b-drug-information/abstract-text/27400984/pubmed" id="27400984" target="_blank">27400984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rae-Grant.1">
<a name="Rae-Grant.1"></a>Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. https://download.lww.com/wolterskluwer_vitalstream_com/PermaLink/WNL/A/WNL_2018_04_19_RAEGRANT_NEUROLOGY2017835181R1_SDC3.pdf. Published April 2018. Accessed January 29, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25185209">
<a name="25185209"></a>Romero RS, Lünzmann C, Bugge JP. Pregnancy outcomes in patients exposed to interferon beta-1b. <i>J Neurol Neurosurg Psychiatry</i>. 2015;86(5):587-589. doi: 10.1136/jnnp-2014-308113.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-beta-1b-drug-information/abstract-text/25185209/pubmed" id="25185209" target="_blank">25185209</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24102425">
<a name="24102425"></a>Rommer PS, Zettl UK, Kieseier B, et al. Requirement for safety monitoring for approved multiple sclerosis therapies: an overview. <i>Clin Exp Immunol</i>. 2014;175(3):397-407. doi:10.1111/cei.12206<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-beta-1b-drug-information/abstract-text/24102425/pubmed" id="24102425" target="_blank">24102425</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7739724">
<a name="7739724"></a>Sheremata WA, Taylor JR, Elgart GW. Severe Necrotizing Cutaneous Lesions Complicating Treatment With Interferon Beta-1b. <i>N Engl J Med.</i> 1995;332(23):1584.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-beta-1b-drug-information/abstract-text/7739724/pubmed" id="7739724" target="_blank">7739724</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26920382">
<a name="26920382"></a>Thiel S, Langer-Gould A, Rockhoff M, et al. Interferon-beta exposure during first trimester is safe in women with multiple sclerosis-a prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry. <i>Mult Scler</i>. 2016;22(6):801-809. doi:10.1177/1352458516634872<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-beta-1b-drug-information/abstract-text/26920382/pubmed" id="26920382" target="_blank">26920382</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8566 Version 212.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
